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ABSTRACT
Objective: To report on the rate of 30-day
readmission and the rate of additional or revision
surgery within 12 months following total ankle
replacement (TAR).
Design: A data-linkage study of the UK National Joint
Registry (NJR) data and Hospital Episodes Statistics
(HES) database. These two databases were linked in a
deterministic fashion. HES episodes 12 months
following the index procedure were isolated and
analysed. Logistic regression was used to model
predictors of reoperation and revision for primary ankle
replacement.
Participants: All patients who underwent primary and
revision ankle replacements according to the NJR
between February 2008 and February 2013.
Results: The rate of 30-day readmission following
primary and revision ankle replacement was 2.2% and
1.3%, respectively. In the 12 months following primary
and revision ankle replacements, the revision rate
(where implants needed to be removed) was 1.2% with
increased odds in those orthopaedic units preforming
<20 ankle replacements per year and patients with a
preoperative fixed equinus deformity. The reoperation
other than revision (where implants were not removed)
in the 12 months following primary and revision TARs
was 6.6% and 9.3%, respectively. Rheumatoid
arthritis, cemented prosthesis and high ASA grade
significantly increased the odds of reoperation.
Conclusions: TAR has a 30-day readmission rate of
2.2%, which is similar to that of knee replacement but
lower than that of total hip replacement. 6.6% of
patients undergoing primary TAR require a reoperation
within 12 months of the index procedure. Early revision
rates are significantly higher in low-volume centres.
INTRODUCTION
Nearly 9 million people in the UK have
sought treatment for osteoarthritis,1 a huge
burden to the National Health Service
(NHS) which spends ∼£10 billion (US$ 14.6
billion, €13.6 billion) annually on musculo-
skeletal care.2
Joint replacements have been available
since the 1960s,3 and hip replacement is one
of the most common orthopaedic interven-
tions carried out globally and is recognised
as one of the most cost-effective interventions
in medicine.3 However, the proliferation of
implants with little outcome data led to the
creation of Joint Registries to capture real-
world data. Indeed, the UK now has one of
the most advanced National Joint Registry
(NJR) programmes in the world4 and has
captured more than 2 million records since
its inception in 2003.5 The NJR now captures
data on all hip, knee, ankle, shoulder and
elbow replacements carried out in England
and Wales. The data of ankle replacements
have been captured on the NJR since April
2010, and although an ankle replacement is
a less common procedure compared to a hip
or knee replacement, the UK registry that
consists of 2554 ankle replacements makes
this the largest database of its kind in the
world.5
The burden of ankle arthritis is growing,
and, in the UK, ∼29 000 patients with symp-
tomatic ankle arthritis present to ankle specia-
lists every year.6 If non-operative interventions
have failed, two main surgical treatment
options are available, ankle arthrodesis
(fusion) or total ankle replacement (TAR). At
Strengths and limitations of this study
▪ World’s largest cohort of ankle replacements
from a joint registry.
▪ Data-linkage methodology reduces biases that
are present in single surgeon, single centre
reports of ankle replacement.
▪ Limited by linkage rate of 73%.
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present, ∼3000 procedures are performed each year by
the NHS;7 of which the ratio of fusion to replacement is
approximately 2:1.6
TAR has been shown to provide patients with an
improved functional outcome,8 and an increasing
patient demand, coupled with evidence of the TAR’s
cost-effectiveness,9 is likely to see a rise in the use of this
technology over the coming years. However, there are
more than 15 types of prostheses available on the
market with published survival rates of TAR varying
between 65% and 96% at 10 years and a cumulative
annual failure rate of 1.2%,8 which is a signiﬁcantly
higher failure rate than that of hip replacements (which
is about 0.76%).5
Patients with ankle arthritis need to have access to
quality and outcome data to enable informed decision-
making,10 and the aim of the current study was to report
on the reoperation and revision rate within a year from
the index TAR by linking the UK NJR to the Hospital
Episodes Statistics (HES) database, which captures data
on all NHS admissions and operations.
In addition, 30-day readmission rates are used in the
UK and internationally as a marker of quality of care,11
and in the UK the data are published by the Health and
Social Care Information Centre (HSCIC) routinely for
hip and knee replacements12 but not for TAR. Using
similar methodology, we, therefore, also aimed to deﬁne
the 30-day readmission rate following TAR.
METHODS AND MATERIALS
Data linkage
Data from the NJR were linked to HES data in a determin-
istic fashion. Deterministic linkage requires an exact
match of the ﬁelds being linked from data sets in order to
say that they are from the same patient. This is in contrast
to the probabilistic linkage, which estimates the likelihood
that two records are for the same individual, even if they
disagree on some ﬁelds.13 The linkage was conducted by
the HSCIC. This was in line with best linkage practice with
application of the ‘separation principle’ to allow the most
ethical workﬂow.14 This principle is used to protect patient
data with patient-identifying components, and clinical
components of a data set are kept separate. Identifying
data are used by a group to perform data linkage, whereas
non-identifying data are used by the research group to
perform the analysis. As there was an exact deterministic
linkage between the common ﬁelds in data sets, all of
these revision and reoperation procedures from the HES
data set had a linked A1 (Primary TAR) NJR form that
contained the demographic data for analysis from the
patient’s primary procedure.
A total of 1627 NJR records had more than 12 months
of time following the index procedure and hence were
linked. The 1627 NJR records were linked to 5 years of
HES records. The NJR-HES linkage was based on a hier-
archy of deterministic criteria on the basis of nine ﬁelds
(ﬁgure 1). NJR data were captured on minimal data set
forms that were completed by the surgeon at the time of
surgery and submitted by the performing hospital. This
is a mandated requirement in the UK NHS. For a
primary ankle replacement, the form is entitled an A1
form and, for a revision ankle replacement, the form is
entitled an A2 form.15 Patient demographics such as
patient age, gender and body mass index (BMI) are cap-
tured in these forms. The unit where the surgery is per-
formed is also captured with details of the grade of
surgeon who performed the surgery. The grade of
surgeon is subdivided into a consultant surgeon and
trainee. Indications for surgery and details of preopera-
tive deformity and range of motion are also included in
these forms. Furthermore, the prosthesis type, surgical
approach, associated procedures, intraoperative compli-
cations and prophylaxis against venous thromboembolic
disease are recorded.16 17
Prosthesis type
The data included 10 brands of ankle prosthesis. The
most frequently used ankle prosthesis was the Mobility
(DePuy Synthes, UK) (56%) followed by the Zenith
(Corin, UK) (20%). Mobile-bearing prostheses were the
most frequently used with ﬁxed bearing use in <1% of
cases (ﬁgure 2). The Mobility implant was withdrawn
from the market in June 2014.
Identification of concurrent procedures
Concurrent procedures that took place at the time of
primary or revision TAR were identiﬁed from the NJR
data alone as they capture the details on the A1 and A2
forms. Concurrent procedures then formed part of the
regression analysis of reoperation and revision. The
Figure 1 Flow chart to illustrate the linkage process.
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frequency of concurrent procedures with primary and
revision TARs was 31% and 57%, respectively. The most
frequent procedure was Achilles lengthening followed
by a calcaneal osteotomy (ﬁgures 3 and 4).
Identification of 30-day readmssion
From the linked data set, all the index procedures with
an HES entry within 30 days of the index procedure
were isolated. These were examined for the ICD-10 diag-
nostic codes and determined the rate and reason for
readmission.
Definition of revision and reoperation
In this study, we used the deﬁnition of revision
accepted by the NJR, which is “any operation leading to
exchange or removal of any of the prosthetic com-
ponents with the exception of incidental exchange of
the polyethylene insert in a mobile bearing (three-
component) ankle replacement”.18 Other surgeries such as
joint debridement, washout or adjacent joint surgery
would constitute a reoperation other than revision. The
rate of reoperation used in this paper included all
revisions.
Figure 2 Frequency of use of
ankle prosthesis brands in the
UK.
Figure 3 Frequency of
concurrent procedures performed
with primary TAR. TAR, total
ankle replacement.
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Identification of reoperation and revision
Reoperation and revision were identiﬁed using the
linked NJR-HES data set. OPCS-4 (Ofﬁce of Population
Censuses and Surveys Classiﬁcation of Interventions and
Procedures V.4) is the procedural classiﬁcation used by
clinical coders within NHS hospitals in the UK. OPCS
codes were used to identify arthroscopy, bone debride-
ment, calcaneal osteotomy, soft tissue operations,
wound-related operations, removal of metalwork and
subtalar fusion in the 12 months following the index
operation. Removal of metalwork pertained to all metal-
work unrelated to the implant (that was not the tibial or
talar component of the TAR).
Statistical methods
Analysis was performed using R V.3.0.2 (R Foundation
for Statistical Computing, Vienna, Austria). Initially, uni-
variate analysis was performed with primary ankle repla-
cements and revision data set to analyse reoperation as a
whole. The Shapiro-Wilk test was used to establish
whether data were normally distributed. In the case of
descriptive statistics, Mann-Whitney or independent
sample t-test was used for continuous variables. For cat-
egorical data, χ2 or ﬁsher exact test was used.
Logistic regression was used to model predictors of
speciﬁc reoperations and was only used with the primary
ankle replacement data set. Every model was adjusted
for patient characteristics including age, BMI, comorbid-
ity and ASA grade. Multiple regression models were con-
ducted in stepwise forwards and backwards fashions. We
used the Akaike information criterion (AIC) to calibrate
the model, which is a robust and objective way to deter-
mining which model is most parsimonious.19 20
Comorbid conditions were deﬁned using the Royal
College of Surgeons Charlson Score applied to HES
records in the 12 months preceding the index operation
for every patient. This is a validated tool, that is, a count
of chronic comorbid conditions that may affect the
outcome of surgery.21
For the purpose of analysis, age was divided into three
groups: <65, 65–75 and >75. The BMI was divided into
three categories. A BMI of 18.5–25 was classiﬁed as
normal, and if patients’ BMI values were lower and
higher than these values, we classify them as under-
weight and overweight, respectively. Reoperation was
Figure 4 Frequency of
concurrent procedures performed
with revision TAR. TAR, total
ankle replacement.
Table 1 OPCS codes used to identify reoperation for the
HES data set
Reoperation type
OPCS (Office of Population
Censuses and Surveys) codes
Arthroscopy Y767, Y223, W881, W833, W822,
W843, W848
Bone debridement W815, W082, W712, W801, W803,
Y055, W336
Calcaneal
osteotomy
W132, X251
Soft tissue
operations
T558, Z872, O271, T705, A661,
W784, T963, W768, T691, W725,
T705, T644, T748
Wound/infection
related
S571, S577, S573, S279, S274,
S352, T761
Removal of
metalwork
W283
Subtalar fusion W043, W041
Revision W443, W444, W453, W455, W432,
W641, W621, W611, W613, W450,
W603, Y032, W433, W434, W444,
W453
4 Zaidi R, et al. BMJ Open 2016;6:e011332. doi:10.1136/bmjopen-2016-011332
Open Access
also analysed in the context of unit volume. We classiﬁed
the units into high volume units where 20 ankle replace-
ments or more per year were carried out and low
volume units where <20 ankle replacements per year
were performed. The reason for this classiﬁcation was
that, in a primary analysis, we identiﬁed that those units
performing more than 20 ankle replacements per year
(19 units) accounted for half of all ankle replacements
performed and those that did <20 ankle replacements
per year (163 units) accounted for the other half.
Indications for TARs on the NJR data set are divided
into ‘osteoarthritis’, ‘rheumatoid arthritis’, ‘other inﬂam-
matory arthropathy’ and ‘other’. Inﬂammatory arthropa-
thy includes psoriatic arthritis, pseudogout, ankylosing
spondylitis, juvenile idiopathic arthritis and systemic
lupus erythematosus.
RESULTS
There were a total of 1627 NJR records comprising 1522
primary operations and 105 revisions. The overall match
rate with HES was 73% with 1110 matched primary proce-
dures and 75 revisions. Using the OPCS codes (table 1)22
for different types of reoperation, we searched linked epi-
sodes for occurrences after the index procedure.
30-Day readmission rate
The rate of 30-day readmission following primary and
revision TARs was 2.2% (95% CI 2.1% to 2.3%) and
1.3% (95% CI 0.9% to 2.3%), respectively. There were
25 readmissions; of which, 9 (36%) were for wound
infections, 6 (24%) were for medical issues (including
cardiovascular and respiratory issues), 5 (20%) were for
reoperation, 3 (12%) were due to fractures around the
prosthesis and 2 (8%) were due to pulmonary
embolism.
Reoperation rate
The rate of reoperation within 12 months of the primary
and revision TARs was 6.6% (95% CI 6.5% to 6.64%) and
9.3% (95% CI 8.6% to 10.6%), respectively (table 2).
A total of 73 primary ankle replacements had 83 reopera-
tions and 7 revision ankle replacements had 8 reopera-
tions. The odds of reoperation with a primary TAR were
increased with rheumatoid arthritis, cemented opera-
tions and increasing ASA grade (table 3). With revision
operations, no risk factors were shown to be signiﬁcant
(table 4).
Arthroscopy post-primary TAR
The rate of arthroscopy (n=12) was 1.1% (95% CI 1% to
1.14%) at a mean of 209 days (SD ±99.3) with the signiﬁ-
cant risk factors being preoperative ﬁxed equinus and
preoperative reduced plantar ﬂexion (to only 5–15°)
(table 5).
Bone debridement post-primary TAR
The rate of bony debridement (n=6) post-TAR was
0.54% (95% CI 0.5% to 0.6%) at a mean of 112 days
(SD ±98.3) (table 2). Rheumatoid arthritis was the only
signiﬁcant predictor with an increase in odds of 2.5
(table 5).
Calcaneal osteotomy
The rate of a calcaneal osteotomy (n=4) following TAR
was 0.4% (95% CI 0.3% to 0.42%) at a mean of 200 days
(SD ±72.6) (table 2). There was a ﬁvefold increase in
risk for having this with a concurrent lateral ligament
reconstruction (table 5).
Soft tissue operations
The rate of soft tissue operations was 0.4% (95% CI
0.3% to 0.42%) at a mean of 180 (SD ±135) days. Six
Table 2 Rate and mean time to reoperation following primary and revision ankle replacements
Operation n Rate within 12 months
Mean time to re-op
(days, SD)
Primary TAR
Bone debridement 6 0.54% (95% CI 0.5% to 0.6%) 112 (98)
Calcaneal osteotomy 4 0.4% (95% CI 0.3% to 0.42%) 200 (72.6)
Ligamentous 4 0.4% (95% CI 0.3% to 0.42%) 179.5 (135)
Wound/infection related 5 0.45% (95% CI 0.41% to 0.51%) 89.7 (83.12)
Removal of metalwork 10 0.9% (95% CI 0.87% to 0.96%) 200 (55.6)
Revision 13 1.2% (95% CI 1.1% to 1.23%) 181.9 (124.9)
Arthroscopy 12 1.1% (95% CI 1% to 1.14%) 208.8 (99.4)
Subtalar fusion 3 0.3% (95% CI 0.23% to 0.33%) 251 (174.5)
Other 16 1.44% (95% CI 1.4% to 1.5%) 178.6 (111)
Total 73 6.6 (95% CI 6.5% to 6.64%)
Revision TAR
Ankle fusion 2 2.7% (95% CI 2.2% to 3.6%) 242.2 (164)
Removal of metalwork 5 6.7% (95% CI 6.2% to 7.6%) 197.2 (126)
Total 7 9.3% (95% CI 8.8% to 10.3%)
BMI, body mass index; CI, confidence interval; F, female; n, number in group; NHS, national health service; OR, odds ratio; n, Number of
patients; re-op, reoperation; Ref, reference value; SD, standard deviation; TAR, total ankle replacement.
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procedures were performed in four patients to address
the gastrocnemius, peroneal tendons, tibialis posterior,
tibialis anterior and the joint capsule. Cemented TAR
and having a ﬁbular osteotomy during the initial proced-
ure increased the odds of these procedures (table 5).
Wound-related operations
A total of 13 wound-related operations were per-
formed in 5 patients. The rate of these procedures in
12 months following TAR was 0.45% (95% CI 0.41% to
0.51%) at a mean of 38 days (SD ±19.4). Each of three
patients had a single procedure, and two patients had
two procedures. Two patients had vascularised skin
ﬂaps, and three had the application of a Vacuum
Assisted Closure (VAC) dressing. The odds of this type
of reoperation were signiﬁcantly increased in patients
with rheumatoid arthritis, cemented prosthesis or con-
current subtalar or talonavicular fusion (table 5).
Table 3 Univariate analysis of comparing reoperation versus no-reoperation within 12 months following primary ankle
replacement surgery
12 months following primary total ankle replacement
Reoperation No-reoperation
Age n (proportion) n (proportion) OR (95% CI, p value)
<65 31 (0.43) 395 (0.38) Ref
65–74 21 (0.29) 376 (0.36) 0.7 (0.4 to 1.3, p=0.24)
>75 20 (0.28) 267 (0.26) 0.9 (0.5 to 1.8, p=0.87)
Length of stay Mean (range) Mean (range)
4.6 (0–46) 3.8 (0–41) p=0.25
BMI n (proportion) n (proportion) OR (95% CI, p value)
Underweight 1 (0.03) 4 (0.006) 5 (0.1 to 62, p=0.2)
Normal 6 (0.18) 122 (0.2) Ref
Overweight 16 (0.47) 258 (0.42) 1.3 (0.5 to 4, p=0.6)
Obese 11 (0.32) 237 (0.38) 0.9 (0.3 to 3.2, p=0.9)
Missing=455
Gender/F 42.5% 43.1%
Indications n (proportion) n (proportion) OR (95% CI, p value)
Osteoarthritis 52 (0.72) 891 (0.86) Ref
Rheumatoid arthritis 13 (0.18) 95 (0.09) 2.3 (1.2 to 4.6, p=0.008)
Inflammatory 3 (0.04) 20 (0.02) 2.6 (0.5 to 9, p=0.12)
Other 4 (0.06) 32 (0.03) 2.1 (0.5 to 6.4, p=0.16)
Operation n (proportion) n (proportion) OR (95% CI, p value)
Uncemented 69 (0.96) 1023 (0.99) Ref
Cement 3 (0.04) 12 (0.01) 3.7(1.2 to 14, p=0.03)
Hybrid 0 (0) 3 (0.002) –
Approach n (proportion) n (proportion) OR (95% CI, p value)
Anterior 69 (0.99) 1000 (0.98) Ref
Lateral 1 (0.01) 7 (0.01) 2.1 (0.05 to 16, p=0.42)
Ant-lateral 0 (0) 10 (0.01) –
Missing=23
Organisation n (proportion) n (proportion) OR (95% CI, p value)
NHS 64 (0.88) 918 (0.88) Ref
Independent hospital (NHS funded) 4 (0.06) 71 (0.07) 0.8 (0.2 to 2.3, p=0.68)
Independent treatment centre
(NHS funded)
4 (0.06) 49 (0.05) 1.2 (0.3 to 3.4, p=0.77)
Grade of surgeon n (proportion) n (proportion) OR (95% CI, p value)
Consultant 69 (0.96) 975 (0.94) Ref
Other 3 (0.04) 63 (0.06) 0.7 (0.1 to 2.2, p=0.8)
ASA n (proportion) n (proportion) OR (95% CI, p value)
1 4 (0.05) 155 (0.15) Ref
2 53 (0.73) 722 (0.7) 2.8 (1.1 to 11, p=0.04)
3 15 (0.21) 157 (0.15) 3.9 (1.2 to 16, p=0.01)
4 0 (0) 4 (0.004) –
Charlson n (proportion) n (proportion)
0 73 (1.0) 1090 (0.98)
1 0 (0) 18 (0.02)
2 0 (0) 4 (0.004)
ASA, American Society of Anesthesiologists; BMI, body mass index; CI, confidence interval; F, female; n, number of patients; NHS, National
Health Service; OR, odds ratio; Ref, reference value; SD, standard deviation.
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Removal of metalwork
The rate of metalwork removal (n=10) was 0.9% (95%
CI 0.87% to 0.96%) at a mean of 200 days (SD ±96)
(table 2). Rheumatoid arthritis was the only signiﬁcant
predictor for this procedure (table 5).
Subtalar fusion
Subtalar fusion was carried out in three patients, and
the rate of subtalar fusion was 0.3% (95% CI 0.23% to
0.33%) at a mean of 251 days (SD ±175) (table 2). No
predictors emerged for this procedure (table 5).
Revision
The revision rate in the 12 months following TAR was
1.2% (95% CI 1.1% to 1.23%) (table 2). Three of these
were full revisions of the ankle replacement and had the
corresponding record for revision on the NJR (an NJR
A2 form was submitted), four were converted to ankle
fusions (but a corresponding NJR A2 form was not sub-
mitted) and six were revisions of just one component
(again without the NJR A2 form). Therefore, 10 of the
13 (77%) revisions were identiﬁed only through the
HES linkage and would not have been identiﬁed if reli-
ance were only on the NJR forms being submitted.
Fifty-four per cent of the revisions were performed as
result of loosening or fracture of any of the three com-
ponents. The odds of revision were signiﬁcantly higher
in those orthopaedic units performing <20 ankle repla-
cements per year and patients with a preoperative ﬁxed
equinus deformity (table 5).
DISCUSSION
This paper constitutes the ﬁrst output from the world’s
largest database of ankle replacements (the UK NJR)
and has shown 30-day readmission rates following
primary and revision TARs to be 2.2% and 1.3%, respect-
ively. The 30-day readmission rate is a proxy measure for
quality of care used by the NHS, and this rate for TAR is
comparable to the reported 30-day readmission rate fol-
lowing knee replacement (2%)23 but lower than the
reported rate for hip replacement (5.3%).24 These
results support the cause for TAR to be offered as
readily as any other lower limb arthroplasty from a
quality of care point of view.
The reoperation rate within 12 months following a
primary TAR was 6.6%. This rate is lower than those for
hip25 and knee replacements,26 which have reoperation
rates, within 12 months of the index procedure, of
12.3% and 8%, respectively.
We identiﬁed three signiﬁcant predictors for TAR:
rheumatoid arthritis, cemented operations and increas-
ing ASA grade. Although rheumatoid arthritis and high
ASA grade seem straightforward, it is not clear whether
Table 4 Univariate analysis of comparing reoperation versus no-reoperation within 12 months following revision ankle
replacement surgery
12 months following revision ankle replacement
Reoperation No-reoperation
Age n (proportion) n (proportion) OR (95% CI, p value)
<65 2 (0.29) 34 (0.5) Ref
65–74 4 (0.57) 19 (0.28) 3.5 (0.4 to 40, p=0.2)
>75 1 (0.14) 15 (0.22) 1.1 (0.01 to 22, p=0.1)
Length of stay mean (range) mean (range)
3.6 (1-6) 4.3 (1–12) p=0.78
BMI n (proportion) n (proportion) OR (95% CI, p value)
Underweight 1 (0.25) 0 (0) –
Normal 1 (0.25) 5 (0.14) Ref
Overweight 2 (0.5) 30 (0.86) 0.3 (0.02 to 24, p=0.41)
Missing=36
Gender/F 43% 44%
Operation n (proportion) n (proportion) OR (95% CI, p value)
Uncemented TAR 2 (0.5) 38 (0.78) Ref
Hybrid 1 (0.25) 9 (0.18) 2.1 (0.3 to 44, p=0.5)
TTC nail 1 (0.25) 2 (0.04) 9.5 (0.1 to 250, p=0.2)
Missing=22
ASA n (proportion) n (proportion) OR (95% CI, p value)
1–2 2 (0.29) 14 (0.21) Ref
3–4 5 (0.71) 54 (0.79) 0.7 (0.1 to 11, p=0.64)
Charlson n (proportion) n (proportion)
0 7 (1.0) 67 (0.98)
1 0 (0) 1 (0.02)
2 0 (0) 0 (0)
ASA, American Society of Anesthesiologists; BMI, body mass index; CI, confidence interval; F, female; n, number of patients NHS, national
health service; OR, odds ratio; Ref, reference value; SD, standard deviation; TTC, Tibio-Talar-Calcaneal.
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Table 5 Logistic regression of predictors of reoperation following primary total ankle replacement
Revision Arthroscopy Bone debridement
Calcaneal
osteotomy
Ligamentous
operation wound related
removal of metal
work subtalar fusion
OR
(95% CI) p Value
OR
(95% CI) p Value
OR
(95% CI) p Value
OR
(95% CI) p Value OR (95% CI) p Value OR (95% CI) p Value OR (95% CI) p Value OR (95% CI) p Value
Indication
Osteoarthritis Ref Ref Ref Ref Ref Ref Ref Ref
Rheumatoid 1.2
(0.5 to 2.5)
0.11 1.3
(0.5 to 3.2)
0.51 2.5
(0.8 to 6)
0.007 4.2
(0.3 to NA)
0.99 0.024 (NA) 0.99 2.2
(1.1-4.3)
0.028 2.2
(1.2-3.9)
0.006 1.7 (0.6-3.8) 0.23
Inflammatory 2.2
(0.6 to 5)
0.78 0.02
(0.001 to
7.3)
0.98 0.04
(0.001 to 82)
0.99 2.6
(0.1 to NA)
0.99 0.025 (NA) 0.99 0.04 (NA) 0.99 2.6
(0.8-6.4)
0.07 0.05 (NA) 0.99
Other 0.03 (NA) 0.99 0.03
(0.01 to
5.30)
0.97 1.3
(0.5 to 2.7)
0.5 2.6
(0.1 to NA)
0.99 0.026 (NA) 0.99 1.6
(0.9-2.8)
0.08 2.1
(0.7-5)
0.11 0.05 (NA) 0.99
Operation type
Uncemented Ref Ref Ref Ref Ref Ref Ref Ref
Cemented 0.05 (NA) 0.99 1.8 (NA) 0.99 0.04 (NA to
77)
0.99 2.3 (NA) 0.99 4.5
(1.1 to 14)
0.02 6.1
(1.3-31)
0.01 0.03 (NA) 0.99 0.05 (NA) 0.97
Hybrid 2.4
(0.7 to 6.1)
0.11 1.5 (NA) 0.98 0.04 (NA to
77)
0.99 6.4 (NA) 0.99 0.03 (NA) 0.99 0.02 (NA) 0.99 0.02 (NA) 0.99 0.05 (NA) 0.95
Approach to ankle
Anterior Ref Ref Ref Ref Ref Ref Ref Ref
Ant-lat 0.03 (NA) 0.99 1.04
(0.02 to 4.4)
0.99 0.9
(0.02 to 7.3)
0.99 7
(0.1 to NA)
0.99 0.3 (NA) 0.99 0.07 (NA) 0.99 0.22 (NA) 0.99 0.42 (NA) 0.99
Lateral 0.03(NA) 0.99 1.7 (NA) 0.99 0.02
(0.001 to 68)
0.99 1.45
(0.1 to NA)
0.99 0.3 (NA) 0.99 1.2
(1.01-7.6)
0.025 0.22 (NA) 0.99 0.42 (NA) 0.94
Organisation
NHS Ref Ref Ref Ref Ref Ref Ref Ref
Ind. hosp 1.02
(0.4 to 2.1)
0.96 1.9
(0.6 to 4)
0.18 1.5
(0.05 to 3.3)
0.4 0.99
(0.1 to NA)
0.99 1.5
(0.5 to 3.3)
0.99 0.02 (NA) 0.99 0.23 (NA) 0.99 0.035 (NA) 0.94
ITC 1.1
(0.4 to 2.4)
0.76 2
(1.01 to 4.4)
0.05 0.02
(0.001 to 23)
0.99 1.1
(0.6 to NA)
0.99 0.03
(0.001-15)
0.99 0.01 (NA) 0.99 0.22 (NA) 0.99 0.035 (NA) 0.95
Unit volume
>20 Ref Ref Ref Ref Ref Ref Ref Ref
<20 1.6
(1.1 to 2.5)
0.04 1.2
(0.7 to 2.1)
0.6 0.9
(0.5 to 1.7)
0.716 0.47
(0.01 to
9.6)
0.99 0.9
(0.5-1.6)
0.69 1.1
(0.7-1.6)
0.74 0.52
(0.2-0.9)
0.062 0.03 (NA) 0.91
Pre-op deformity
Neu Ref Ref Ref Ref Ref Ref Ref Ref
Valgus 0.03 (NA) 0.99 0.16
(0.001 to 13)
0.99 0.03
(0.001 to 14)
0.99 7.8
(0.5 to NA)
0.99 0.33 (NA) 0.99 0.03 (NA) 0.99 1.8
(0.8-3.6)
0.14 1.9
(0.6-5.3)
0.2
Varus 1.2
(0.4 to 2.6)
0.66 0.6
(0.3 to 4.4)
0.71 0.03
(0.004 to 45)
0.99 1
(0.1 to 74)
0.99 0.33 (NA) 0.99 1.6
(0.8-2.8)
0.14 1.2
(0.4-2.7)
0.63 1.7
(0.6-4.8)
0.3
Pre-op dorsiflexion
5–10 Ref Ref Ref Ref Ref Ref Ref Ref
Neu 1.7
(0.7 to 4.8)
0.23 1.02
(0.6 to 1.7)
0.922 0.03
(0.002 to 15)
0.99 1
(0.2 to 51)
0.99 1.1
(0.4 to 2.2)
0.89 0.9
(0.5 to 1.4)
0.6 0.5
(0.2 to 0.9)
0.06 0.03 (NA) 0.99
Fixed eq 3.53
(1.1 to 12)
0.026 1.9
(1.3 to 3.3)
0.03 1.7
(0.8 to 4.7)
0.23 1
(0.4 to 43)
0.99 0.6
(0.2 to 1.2)
0.22 0.91
(0.3 to 1.8)
0.81 0.8
(0.3 to 1.6)
0.54 0.8
(0.3 to 1.8)
0.61
Continued
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Table 5 Continued
Revision Arthroscopy Bone debridement
Calcaneal
osteotomy
Ligamentous
operation wound related
removal of metal
work subtalar fusion
OR
(95% CI) p Value
OR
(95% CI) p Value
OR
(95% CI) p Value
OR
(95% CI) p Value OR (95% CI) p Value OR (95% CI) p Value OR (95% CI) p Value OR (95% CI) p Value
Pre-op plantarflexion
16–45 Ref Ref Ref Ref Ref Ref Ref Ref
5–15 1.04
(0.3 to 4)
0.95 2.1
(1.1 to 4.9)
0.037 4.5
(0.8 to 45)
0.99 1 (NA) 0.98 3.6
(0.6 to 6.8)
0.25 3.04
(0.8 to 20)
0.16 0.8
(0.5 to 1.3)
0.35 0.34
(0.01 to 3.5)
0.4
Number of associated procedures
0 Ref Ref Ref Ref Ref Ref Ref Ref
1 0.6
(0.2 to 1.2)
0.2 0.1
(0.02 to 5.4)
0.99 0.9
(0.1 to 32)
1 1.4
(0.6 to 3.3)
0.4 1.4
(0.7 to 12)
0.9 0.9
(0.1 to 5.6)
0.9 1.6
(0.8 to 3)
0.1 0.8
(0.01 to 16)
0.9
2 1.5
(0.1 to 7.2)
0.9 0.2
(0.1 to 7.4)
0.99 0.9
(0.1 to 23)
1 2.4
(0.2 to 22)
0.9 2.3
(0.6 to 6.9)
0.1 5.2
(1.5 to 36)
0.9 1.8
(0.4 to 5)
0.8 0.7
(0.1 to 9.6)
0.9
3 0.2 (NA) 0.9 0.1
(0.01 to 13)
1 1.1
(0.3 to 15)
1 2.9
(0.4 to 4.4)
0.8 1
(0.1 to 9.8)
0.9 6.6
(0.4 to 9.1)
0.9 1.2
(0.4 to 3.1)
0.9 1.1
(0.7 to 6.8)
0.9
Type of associated procedure
None Ref Ref Ref Ref Ref Ref Ref Ref
Subtalar fusion 0.2
(0.1 to 14)
0.95 0.02
(0.01—14)
0.99 1.5
(0.01 to NA)
1 0.2
(0.1 to 6.7)
0.97 0.03
(0.01 to 78)
0.99 2
(1.1 to 3.8)
0.04 1.7
(0.8 to 3.3)
0.1 0.04 (NA to
26)
0.99
Talonavicular fusion 2
(0.1 to 4.6)
0.97 0.02
(0.001 to 17)
0.96 1.1
(0.01 to 23)
0.89 0.2
(0.01 to 12)
0.98 0.04 (NA to
35)
0.98 2.8
(1.2 to 5.8)
0.01 0.04 (NA to
9.4)
0.98 0.05 (NA to
35)
0.99
Calcaneal osteotomy 0.5
(0.1 to 12)
0.97 0.01
(0.001 to 9)
0.99 1.4
(0.7 to 25)
0.9 1.9
(0.1 to 16)
0.98 1.5
(0.5 to 3.3)
0.36 1.7
(0.5 to 3.9)
0.3 0.03 (NA to
24)
0.99 0.04 (NA to
27)
0.99
Lengthening of achilles 1.1
(0.4 to 2.5)
0.8 0.02
(0.01 to 11)
0.97 0.8
(0.4 to NA)
1 2
(0.4 to 32)
0.96 1.2
(0.6 to 2.2)
0.5 1.1
(0.4 to 2.1)
0.96 0.9(0.4 to
1.9)
0.89 0.03 (NA to
13)
0.99
Fusion distal
tibiofibular joint
1.8
(0.2 to 19)
1 0.01 (NA to
23)
1 0.1 (NA) 1 0.2 (NA) 1 0.06 (NA to
31)
0.99 0.02(NA to
21)
0.99 0.09 (NA to
57)
0.99 0.09 (NA to
19)
0.99
Fibula osteotomy 0.2
(0.01 to
NA)
0.99 0.02
(0.001 to 31)
0.93 0.9 (NA) 1 0.2
(0.01 to
NA)
0.99 5
(1.3 to 18)
0.02 0.06 (NA to
11)
0.98 0.05(NA to
44)
0.99 0.07 (NA to
43)
0.94
Medial malleolar
osteotomy
0.03
(0.002 to
15)
0.99 0.01 (NA to
12)
0.99 0.9 (NA) 1 0.2
(0.03 to
NA)
0.99 3.3
(0.9 to 9.8)
0.06 0.03
(0.001 to 13)
0.97 0.04 (NA to
38)
0.99 0.06 (NA to
20)
0.99
Lateral ligament recon 0.3
(0.1 to 22)
0.7 0.02
(0.01 to 34)
0.99 1.3
(0.01 to NA)
1 5
(1.2 to 17)
0.017 0.04
(0.01 to 35)
0.98 0.05(0.01 to
35)
0.98 0.04 (NA to
19)
0.99 0.06 (NA to
25)
0.94
Medial ligament recon 1.7
(0.6 to 11)
0.99 0.01 (NA to
23)
1 1
(0.01 to NA)
1 0.2
(0.01 to
NA)
0.99 0.05 (NA to
13)
0.98 0.05
(0.01 to 55)
0.92 0.04 (NA to
10)
0.99 0.06 (NA to
98)
0.99
Adjusted for age, gender and comorbidity.
ITC, Independent Treatment Centre.
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emented procedures increase complications or whether
surgeons elect to use cement in more complicated pro-
cedures,27 explaining the higher reoperation rate.
Indeed, the majority (>95%) of TARs reported in the
NJR are uncemented.
The reoperation rate following revision was 9.3%, but
numbers were small, and no predictors emerged. Previous
studies with longer follow-up have shown age to be a pre-
dictor of reoperation with increased risk at the extremes of
age, but there was no indication of this from our data.28
We found that the reoperation rate related to wound
complications within 1 year of the index primary TAR
was 0.45%, with rheumatoid arthritis being a signiﬁcant
risk factor. This is a similar ﬁnding to that found in the
study of Raikin et al29, which showed a 14-times increase
in wound complications requiring reoperation in
patients with rheumatoid arthritis.
In our paper, we have deﬁned revision as being “any
operation leading to exchange or removal of any of the
prosthetic components with the exception of incidental
exchange of the polyethylene insert in a mobile bearing
(3 component) ankle replacement”.18 All other proce-
dures are referred to as reoperations other than revision.
The revision rate within 1 year of primary TAR was 1.2%.
The majority of these were change in only one compo-
nent. A meta-analysis of joint registry data from Sweden,
Finland, Norway and New Zealand8 has shown the yearly
failure rate to be 3.2%, almost double that from the UK
thus far, although numbers in the UK registry are much
greater. Scandinavian registries contain a higher propor-
tion of rheumatoid patients compared to the UK regis-
try, ∼36% and –10% (from current work), respectively,
which might explain the difference in the yearly failure
rate.30
A major strength of this study was that we used
another database (HES) to identify revision procedures.
We could have used the intradatabase linkage by trying
to link all the primary procedures on the NJR to revision
procedures; however, this would have greatly underesti-
mated the revision rate as not all revisions were captured
on the NJR resulting in reporting bias.8
TAR performed in a low-volume centre (ie, <20 TAR
operations per year) was found to be a risk factor or an
early implant failure. The reason for the cut-off of 20
was that the analysis identiﬁed that those units perform-
ing more than 20 TAR operations per year (19 units)
accounted for half of all ankle replacements performed
and those that did <20 TAR operations per year
(163 units) accounted for the other half.
This ﬁnding contrasts with a Norwegian registry study
that examined 257 TARs and found no difference in sur-
vival by unit volume.31 This difference may be attribut-
able to the greater power of the current study as a result
of signiﬁcantly larger numbers of TAR included.
Limitations
This study had a limited power to detect risk factors for
speciﬁc reoperations owing to small numbers of patient
end points. Despite this, we retained the conventional
threshold for a statistical signiﬁcance of p=0.05, which
was in keeping with other publications of this type. Some
estimates (eg, cemented prostheses) are based on small
numbers and need to be treated with caution. A further
limitation was the dependence on OPCS-4 procedural
coding systems as any errors in coding may have misrepre-
sented an event. In orthopaedics, 19% of procedures
have been shown to be inaccurately coded, but training
and education combined with continued national audit
of coding have resulted in improvement.32
In this study, we are unable to divide the osteoarthritis
group into primary and post-traumatic osteoarthritis as
these data are not captured in the NJR; however, this dis-
tinction is, in practice, very subjective as it is possible
that patients have a combination of primary and post-
traumatic arthritic changes. Hence, we believe that any
papers that classify primary versus post-traumatic osteo-
arthritis are likely to also be subject to similar errors.
The linkage rate of the NJR data to the HES data was
73%. Of the unlinked data, 22% (365 ankle replace-
ments) were carried out in the independent (private)
sector and there were no relevant HES records to inter-
rogate. Since there are very few emergency admission
units in the private sector, we believe that complications
in the main are picked up in the public sector. However,
we cannot be certain that complications were not dealt
with in the private sector, where no HES record would
be recorded and hence the 30-day readmission rates and
the 1 year reoperation other than revision rates could be
higher as described in this paper.
As with any paper reporting on large national data
sets, data incompleteness can be an issue. With respect
to primary TARs, there were missing data regarding the
BMI and surgical approach (table 3) and the revision
BMI and operation type (table 4). We did not consider
these data had a major impact on the study results.
Compliance with completion of NJR forms is also an
issue. Compliance is the percentage of all TARs that
have been entered into the NJR within a 12-month
period. Compliance for completion of primary TARs in
the NJR has risen from 64% in 2012 to 77% in 2013.5
CONCLUSIONS
The TAR has a 30-day readmission rate of 2.2%, which is
similar to that of a knee replacement but lower than
that of a total hip replacement. Of the patients undergo-
ing primary TAR, 6.6% require a reoperation within
12 months of the primary procedure, and of which 1.2%
will require a revision procedure. The leading patient
factors that increase the risk of reoperation and revision
are rheumatoid arthritis, preoperative deformity and
high ASA grade. In terms of hospital/surgeon factors,
early revision rates are signiﬁcantly higher in low volume
centres.
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